

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

EXHIBIT 1



TEN, Case No. 2024304

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Batra et al.

Serial No. To Be Assigned

Filed:

For: Compressed Tablet Formulation

Art Unit: To Be Assigned

Examiner: To Be Assigned

RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE  
DATE OF DEPOSIT June 28, 2001  
EXPRESS MAIL NO. 952390468US  
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS EXPRESS MAIL, "POST OFFICE TO  
ADDRESSEE" BEFORE 5 P.M. ON THE ABOVE DATE IN  
AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER  
FOR PATENTS, WASHINGTON, D.C. 20231.  
MAILED BY A. P. Crowley

I hereby certify that this correspondence is being deposited with  
the United States Postal Service as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents, Washington,  
D.C. 20231, on the date appearing below.

MERCK & CO., INC

By \_\_\_\_\_ Date \_\_\_\_\_

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number	To Be Assigned
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

To Be Assigned 05/894,92

<b>Filing Date</b>	June 29, 2001
--------------------	---------------

<b>First Named Inventor</b>	<b>Batra et al.</b>
-----------------------------	---------------------

### Group Art Unit

Examiner Name

Attorney Docket Number	20243CA
------------------------	---------

Sheet	1	of	2
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

# FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
2	A	PCT	WO 95/20389		Merck & Co., Inc.	08/03/1995
	B	PCT	WO 96/37457		Merck & Co., Inc.	11/28/1996
	C	PCT	WO 98/52570		Glaxo Group Limited	11/26/1998
	D	PCT	WO 98/30543		Merck & Co., Inc.	07/16/1998
	E	PCT	WO 98/33782		Merck & Co., Inc	08/06/1998
	F	PCT	WO 99/51239		DuPont Pharmaceuticals Co.	10/14/1999
	G	EPO	0 547 000		Sandoz Ltd.	06/16/199
	H	EPO	0 384 600		Riker Laboratories Inc.	08/29/1990

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number

~~To Be Assigned~~

**Filing Date**

June 29, 2001

**First Named Inventor**

Batra et al.

Group Art Unit

Examiner Name

Attorney Docket Number

20243CA

### OTHER NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner**

Date \_\_\_\_\_

12/11/02

Please type a plus sign (+) inside this box → **+**

SUBSTITUTE for PTO/SB03 (08/00) Utility Patent Application Transmittal  
Approved for use through 10/31/2001... 48 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	20243CA -
First Inventor or Application Identifier	Batra et al.
Title	Compressed Tablet Formulation
Express Mail Label No.	EL523906658US

RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

<b>APPLICATION ELEMENTS</b> <i>See MPEP chapter 600 concerning utility patent application contents.</i>		<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)		6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)	
2. <input checked="" type="checkbox"/> Specification [Total Pages 27]		a. <input type="checkbox"/> Computer Readable Form	
3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets ]		b. <input type="checkbox"/> Paper Copy (identical to computer copy)	
[Total Pages 27]		c. <input type="checkbox"/> Statements verifying identity of above copies	
4. Oath or Declaration		<b>ACCOMPANYING APPLICATION PARTS</b>	
a. <input type="checkbox"/> Newly executed (original or copy)		7. <input type="checkbox"/> Assignment papers (cover sheet & document(s))	
b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 14 completed)		8. <input type="checkbox"/> 37 CFR 3.73(b) Statement [Power of Attorney]	
i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).		9. <input checked="" type="checkbox"/> Information Disclosure Statement [Copies of IDS Citations] (IDS/PTO-1449)	
5. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		10. <input checked="" type="checkbox"/> Preliminary Amendment	
14. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:		11. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
<input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No. 09 / 312,617		12. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
Prior application information: Examiner S. Sharath		13. <input type="checkbox"/> Other: _____	
For CONTINUATION OR DIVISIONAL APPLICANTS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.			
<b>15. CORRESPONDENCE ADDRESS</b>			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label			
Customer No. 000210 (Insert Customer No. or Attach bar code here)			
NAME	Kenneth R. Walton		
ADDRESS	Merck & Co., Inc., P. O. Box 2000 - Patent Dept., RY60-30		
CITY	Rahway	STATE	NJ
COUNTRY	USA	ZIP CODE	07065-0907
	TELEPHONE	732-594-3462	FAX 732-594-4720
Name	Kenneth R. Walton	Registration No. (Attorney/Agent)	32,951
Signature	Kenneth R. Walton	Date	6/28/2001

<b>EXPRESS MAIL CERTIFICATE</b>	
DATE OF DEPOSIT	June 28, 2001
EXPRESS MAIL NO.	EL523906658US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, BOX PATENT APPLICATION, WASHINGTON, D.C. 20231	
MAILED BY	DATE 6/28/01

Computer generated form "Transmittal Form Non-PV" (Application Filing Folder) Merck & Co., Inc., 9/28/00



RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

THE PATENT & TRADEMARK OFFICE ACKNOWLEDGES, AND HAS  
STAMPED HEREON, THE DATE OF THE RECEIPT AND THE ASSIGNED  
SERIAL NUMBER OF THE FOLLOWING PATENT APPLICATION:

CASE NUMBER	DATE	ATTORNEY	EXPRESS MAIL <input checked="" type="checkbox"/>
20243CA	June 28, 2001	KRW/kd	EL523906658US
TITLE		J1036 U.S. PTO	
COMPRESSED TABLET FORMULATION		09/894921	
INVENTORS		06/28/01	
Udit Batra, Raymond J. Higgins, Karen C. Thompson and Ashok V. Katdare			
NO. OF PAGES	NO. OF CLAIMS	PAGES OF DRAWING	
27	34	-----	
DECLARATIONS		ACCOUNT CHARGE	
4 inventors		13 - 2755 \$ 962.00	

F1071.3 REV.9/93



EXHIBIT 2

PATE. Case No. 20243CA

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Batra et al.

Serial No. 09/894,921

Filed: June 28, 2001

For: Compressed Tablet Formulation

Art Unit: 1619

Examiner: To Be Assigned

RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97

LOCKE  
NOV 14 2001  
PSARA

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK &amp; CO., INC.

By

Date

11-27-01



# INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

U. S. SERIAL NUMBER	RELATED APPLICATION	
	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Kenneth R. Walton

By: Kenneth R. Walton

Attorney For Applicant(s)

Reg. No. 32951

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3462

Date: November 27, 2001






RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2900

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY <i>Kenneth R. Walter</i>	DATE <i>11-27-01</i>
CASE NUMBER/ <i>20243CA</i>	SERIAL NUMBER <i>09/894,921</i>
DATE FILED <i>June 28, 2001</i>	
APPLICANT <i>Batra et al.</i>	
EXPRESS MAIL NO.	



The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET

*Supplemental*



EXHIBIT 3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Batra et al.		
Serial No.:	09/894,921	Case No.:	20243CA
Filed:	June 28, 2001		
For:	COMPRESSED TABLET FORMULATION		

Art Unit:  
1619

Examiner:  
To Be Assigned

RECEIVED  
OCT 31 2002  
TECH CENTER 1600/2800

DOCKETEL  
DEC 07 2001  
ARBARA REII

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to bring the following co-pending application to the Examiner's attention.

Case 20243P    Serial No. 09/700,946    filed March 12, 2001    Batra et al.

Applicants hereby request that Examiner consider the above-listed co-pending case, initial beside it to indicate that the co-pending application has, in fact, been considered, and return a copy of the initialed page to Applicants. Copies of the original application and pending claims are enclosed.

This statement is being filed more than three months after the filing date, but prior to a first Official Action on the merits. No fee is due.

Respectfully submitted,

By:

Kenneth R. Walton  
Kenneth R. Walton, Reg. No. 32,951  
Attorney for Applicants

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By [Signature] Date 12/7/01

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
Tel.: (732) 594-3462

Date: December 7, 2001




RECEIVED  
OCT 31 2002  
TECH CENTER 1600/250

### P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY <i>Kenneth R. Wilton</i>	DATE <i>12-7-01</i>
CASE NUMBER/ <i>20243CA</i>	SERIAL NUMBER <i>09/894,921</i>
DATE FILED <i>June 28, 2001</i>	
APPLICANT <i>Batra et al.</i>	
EXPRESS MAIL NO.	

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET



*Supplemental*